Le Lézard
Classified in: Health
Subject: PER

Industry Veteran Steve Grenon Joins Lumagenics as Chief Operating Officer


CARY, N.C., Jan. 14, 2020 /PRNewswire/ -- Lumagenics, today announced that veteran technology executive Steve Grenon has joined the company as Chief Operating Officer. 

Lumagenics Logo (PRNewsfoto/Lumagenics)

Effective immediately, Grenon will assume responsibility for engineering, operations and Intellectual Property Development for the organization.  Steve will be responsible for the alignment and prioritization of company technology development and ensuring operational excellence across the company.

Steve is a serial entrepreneur, joining Lumagenics from Johnson and Johnson Surgical Vision where he served as head of R&D on the Dry Eye Business unit after the acquisition in 2017, of his prior startup Company TearScience.  Grenon was the first employee of TearScience and served as VP of R&D.  Under his direction, TearScience was awarded more than 100 patents making them the technology leader in the treatment and diagnostics of Meibomian Gland Disfunction (MGD). 

Prior to TearScience, Steve served as the Chief Technology Officer of a Duke University startup, Volumetrics Medical Imaging, which was the first to innovate and patent ground breaking real-time 3D ultrasound technology.  The company had a successful exit, licensing the technology to several large ultrasound market leaders.  The prototype of the first 3D ultrasound is currently at the Smithsonian.

"We are excited that Steve chose to be part of our team for his next adventure and look forward to adding another success to his portfolio. Steve's strategic vision and expertise will be critical to our product launch and future technology development," said C.G. Gillooly, CEO.

Lumagenics expects to launch their first surface disinfection device commercially in 2020.

About Lumagenics
Lumagenics is a privately held, technology platform company located near Research Triangle Park, North Carolina.  Our mission is to transform today's current disinfection approaches by harnessing UV light to combat pathogens.  For more information, visit lumagenics.com.

For more information contact:                                       
Lumagenics:  Amy Harris
Phone:  919-769-2200
Email:  [email protected]

 

SOURCE Lumagenics


These press releases may also interest you

at 15:00
TELUS Health revealed today the results of its 2024 Drug Data Trends and National Benchmarks Report at its 20th annual TELUS Health Conference, running today and April 30. Diabetes medications remain the leading drug category for eligible private...

at 14:45
With safe seated mammography trending in the U.S., the Samuel U. Rodgers Health Center (Sam Rodgers) reports its use of the Danish made VELA Mammography Chair has provided significant physical benefits for patients, health benefits for mammographers,...

at 14:35
MD Logic Health® is excited to announce a groundbreaking partnership with renowned Nutritional Therapy Practitioner, Liz Wolfe, to launch an innovative new supplement, Daily Aminos+. This collaboration combines MD Logic Health®'s expertise in...

at 14:34
Last week, the Internal Revenue Service (IRS) issued a groundbreaking announcement on the tax treatment of work-life referral services provided to employees under an employer's work-life referral program. This development marks a significant...

at 14:30
Summer Health, a digital health company offering 24/7 pediatric support to parents, announced $11.65M in Series A Funding, co-led by new investor 7wire Ventures and returning investor Lux Capital. Returning investors Sequoia Capital, Metrodora...

at 13:56
Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patientsGastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a rare cancer that...



News published on and distributed by: